BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2015

View Archived Issues

Hepatocyte-tageted insulin gene transfer induces tolerance and protects against T1D

Read More

Sacituzumab govitecan shows acceptable safety profile

Read More

Sanofi extends collaboration with Medicines for Malaria Venture

Read More

Immunovaccine and PharmAthene to develop anthrax vaccine formulated in DepoVax

Read More

Novartis develops LTA4H inhibitors

Read More

Purdue Pharma presents Na1.7 channel blockers

Read More

Orion designs BET inhibitors

Read More

Sunshine Lake Pharma reports 5-HT reuptake inhibitors/5-HT1A receptor agonists

Read More

Vaccine candidate LT-69 confers long-term protection against M. tuberculosis infection in mice

Read More

Idarucizumab rapidly and completely reverses anticoagulant effects of dabigatran in clinical trial

Read More

Coretherapix's allogeneic human cardiac stem cells infusion enters phase I/II clinical trial

Read More

Nintedanib shows potent antifibrotic effects in preclinical models of SSc

Read More

Novel BTK inhibitor shows potential for the treatment of RA

Read More

FDA clears phase IIa study of AR-301 in acute pneumonia to expand into U.S.

Read More

Anika Therapeutics reports data from follow-up study of Cingal

Read More

Seattle Genetics begins Adcetris trial in systemic lupus erythematosus

Read More

Sorrento and NantBioScience to develop small molecule therapies against cancer

Read More

FDA grants fast track designation to Toca-511 & Toca-FC for recurrent glioma

Read More

Ultragenyx reports Fast Track designation and 40-week treatment data of KRN-23 in pedriatic XLH

Read More

Lancaster University researchers plan trial of liragutide in ALS

Read More

NIH grant supports Califia Bio's development of CLFB-1134 to treat cognitive deficits in MS

Read More

FDA approves first COPD biomarker

Read More

OWL to develop companion diagnostic for Galmed's Aramchol

Read More

ORIG3N to generate cells for research into Sturge-Weber syndrome

Read More

Aquinox's AQX-1125 fails to show benefit in phase II COPD trial

Read More

Globavir licenses BC-001 to Sorrento Therapeutics

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing